Drug in new class shows benefit for individuals with cannabis use disorder.

Phase 1 and 2a studies of the first drug in a new pharmacological class to be tested in humans have found that the drug was well‐tolerated in healthy volunteers and inhibited the effects of cannabis in individuals with cannabis use disorder. The drug, AEF0117, is a signaling‐specific inhibitor of the cannabinoid receptor 1 (CB1‐SSi) and appears to reduce cannabis self‐administration without precipitating withdrawal, according to the investigators. Results of the studies were published online June 8, 2023, in Nature Medicine. [ABSTRACT FROM AUTHOR]